RxDoctor Payments Data

Derrick Thiel, DO

Infectious Disease · Brandon, FLNPI 1164510566

Payments from drug & device makers

$803in general payments, 2019–2025

Across 31 payments — averaging $25.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$413
  • AbbVie$345
  • Shionogi Inc$21
  • Gilead$13
  • Johnson & Johnson$11

What the payments were for

  • Food & beverage$803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insmed, Inc.15$413
AbbVie(2 entities)13$345
Shionogi Inc1$21
Gilead1$13
Johnson & Johnson1$11

How this compares

$803 in reported general payments places this provider in the 50th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$241,873
Medicare patients
398
Services billed
4,643

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala72$295,010
CabenuvaCabotegravir/Rilpivirine16$103,004
Egrifta SvTesamorelin Acetate11$81,694
TriumeqAbacavir/Dolutegravir/Lamivudi19$67,830
StribildElviteg/Cob/Emtri/Tenofo Disop12$53,691
DovatoDolutegravir Sodium/Lamivudine18$51,410
TivicayDolutegravir Sodium20$48,152
PrezcobixDarunavir/Cobicistat11$31,584
EdurantRilpivirine Hcl14$21,878
Cefepime Hcl28$6,748
Vancomycin Hcl19$3,594
SymbicortBudesonide/Formoterol Fumarate14$3,307
Doxycycline Hyclate11$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Stribild$13$348,70284 claims
Johnson & JohnsonPrezcobix$11$31,58411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →